Susquehanna International Group, LLP Abb Vie Inc. Put Options Transaction History

Susquehanna International Group, LLP

$560 Billion
Q3 2024

Put Options

29 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	BUY	$163.84 - $199.33 $52 Million - $63.2 Million	317,200 Added 19.55%	1,939,500 $383 Million
Q2 2024 Aug 15, 2024	SELL	$154.79 - $180.76 $38.4 Million - $44.8 Million	-247,800 Reduced 13.25%	1,622,300 $278 Million
Q1 2024 May 07, 2024	SELL	$159.82 - $182.1 $162 Million - $185 Million	-1,013,700 Reduced 35.15%	1,870,100 $341 Million
Q4 2023 Feb 14, 2024	BUY	$137.6 - $154.97 $24.2 Million - $27.3 Million	176,200 Added 6.51%	2,883,800 $447 Million
Q3 2023 Nov 14, 2023	SELL	$133.59 - $154.65 $28.8 Million - $33.4 Million	-215,800 Reduced 7.38%	2,707,600 $404 Million
Q2 2023 Aug 11, 2023	BUY	$132.51 - $164.9 $199 Million - $247 Million	1,499,100 Added 105.25%	2,923,400 $394 Million
Q1 2023 May 16, 2023	SELL	$144.61 - $166.54 $172 Million - $198 Million	-1,190,500 Reduced 45.53%	1,424,300 $227 Million
Q4 2022 Feb 14, 2023	BUY	$138.31 - $165.87 $81.1 Million - $97.3 Million	586,400 Added 28.91%	2,614,800 $423 Million
Q3 2022 Nov 14, 2022	SELL	$134.21 - $153.93 $48.7 Million - $55.9 Million	-363,200 Reduced 15.19%	2,028,400 $272 Million
Q2 2022 Aug 15, 2022	BUY	$137.62 - $174.96 $86.2 Million - $110 Million	626,000 Added 35.46%	2,391,600 $366 Million
Q1 2022 May 16, 2022	SELL	$131.98 - $163.75 $220 Million - $272 Million	-1,663,600 Reduced 48.51%	1,765,600 $286 Million
Q4 2021 Feb 14, 2022	SELL	$107.43 - $135.93 $102 Million - $129 Million	-951,100 Reduced 21.71%	3,429,200 $464 Million
Q3 2021 Nov 15, 2021	SELL	$106.4 - $120.78 $37.2 Million - $42.2 Million	-349,700 Reduced 7.39%	4,380,300 $473 Million
Q2 2021 Aug 11, 2021	BUY	$105.21 - $117.21 $87.9 Million - $97.9 Million	835,400 Added 21.45%	4,730,000 $533 Million
Q1 2021 May 17, 2021	SELL	$102.3 - $112.62 $161 Million - $178 Million	-1,578,400 Reduced 28.84%	3,894,600 $421 Million
Q4 2020 Feb 16, 2021	SELL	$80.49 - $108.67 $23.6 Million - $31.8 Million	-292,700 Reduced 5.08%	5,473,000 $586 Million
Q3 2020 Nov 16, 2020	BUY	$85.91 - $100.83 $22 Million - $25.8 Million	255,600 Added 4.64%	5,765,700 $505 Million
Q2 2020 Aug 14, 2020	SELL	$73.37 - $98.18 $35.2 Million - $47.1 Million	-479,300 Reduced 8.0%	5,510,100 $541 Million
Q1 2020 May 15, 2020	BUY	$64.5 - $97.79 $84.6 Million - $128 Million	1,311,400 Added 28.03%	5,989,400 $456 Million
Q4 2019 Feb 14, 2020	SELL	$72.13 - $90.25 $33 Million - $41.3 Million	-457,800 Reduced 8.91%	4,678,000 $414 Million
Q3 2019 Nov 14, 2019	BUY	$62.98 - $75.72 $84.7 Million - $102 Million	1,345,500 Added 35.5%	5,135,800 $389 Million
Q2 2019 Aug 14, 2019	BUY	$65.7 - $83.98 $90 Million - $115 Million	1,370,500 Added 56.64%	3,790,300 $276 Million
Q1 2019 May 15, 2019	SELL	$77.14 - $90.79 $60.4 Million - $71.1 Million	-783,600 Reduced 24.46%	2,419,800 $195 Million
Q4 2018 Feb 14, 2019	SELL	$77.85 - $96.01 $27.9 Million - $34.4 Million	-358,100 Reduced 10.05%	3,203,400 $295 Million
Q3 2018 Nov 14, 2018	SELL	$88.91 - $98.84 $46.4 Million - $51.6 Million	-522,400 Reduced 12.79%	3,561,500 $337 Million
Q2 2018 Aug 14, 2018	BUY	$89.78 - $106.23 $74.7 Million - $88.4 Million	831,900 Added 25.58%	4,083,900 $378 Million
Q1 2018 May 15, 2018	BUY	$92.01 - $123.21 $73.6 Million - $98.5 Million	799,400 Added 32.59%	3,252,000 $308 Million
Q4 2017 Feb 14, 2018	BUY	$89.56 - $98.21 $63.4 Million - $69.6 Million	708,400 Added 40.61%	2,452,600 $237 Million
Q3 2017 Nov 14, 2017	BUY	$69.85 - $89.22 $122 Million - $156 Million	1,744,200	1,744,200 $155 Million

Others Institutions Holding ABBV

# of Institutions

3,852

Shares Held

1.25B

Call Options Held

16.8M

Put Options Held

12.2M

View Full List

About AbbVie Inc.

Ticker ABBV
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,768,099,968
Market Cap $310B
Description
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...

More about ABBV

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Group, LLP with notifications on news.

Account